Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JohnBelgon Aug 31, 2017 10:20am

130 Views

Post# 26641652

RE:RE:TaiMed company presentation August 2017

Thanks SPCEO1. Yes I mentioned in my post that the graph had older numbers and that they referenced the newer 20-25k October 2016 numbers. But in your thinking about patient target population, do you reckon that in addition to MDR sufferers the AVR intolerant and the non-adherent are additional potential patients for ibalizumab? If so I would think this raises potential sales, is good news for TH.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features